Latest news with #ResearchandDevelopment
India.com
27-07-2025
- Politics
- India.com
Meet GAZAP and NEB-2: Two deadly bombs developed by Turkey, weight is 970 kg, can be dropped from..., India has to...
New Delhi: Turkey has successfully tested its most powerful non-nuclear bombs GAZAP and NEB-2 Ghost. Turkey released a video of the tests of these bombs on July 26-27 during the 17th International Defense Industry Fair (IDEF) 2025 fair held in Istanbul. Why are these bombs so dangerous? Both bombs weigh 970 kg (about 2,000 pounds). They have been designed by the Research and Development (R&D) Center of the Ministry of Defense of Turkey. GAZAP is equipped with a thermobaric warhead. These bombs can be dropped from F-16 fighter jets. The footage shows that this bomb can affect an area of hundreds of square meters. It contains 10 thousand special particles, which spread at a rate of 10.6 particles per square meter after the explosion. The Turkish Defense Ministry said that all the tests of both the bombs have been completed and now it is ready for use. What is Turkey's military development and preparation for? Turkey has rapidly developed its military technology in recent decades. Now it is moving towards self-reliance in the defense sector. The goal of Turkey's defense policy is to reduce dependence on foreign investors and promote indigenous products. For this, Turkey has taken big steps in technology like missiles, armoured vehicles, naval ships and aircraft. Turkey has many missiles, including Tayfun, Siper, Sapan. Tayfun Block-4 is Turkey's first hypersonic ballistic missile, with a range of 800 km and speed more than Mach 5. It weighs 2,300 kilometers and is 6.5 meters long. What will be the impact on India with this test of Turkey? The relationship between India and Turkey has been complex and multifaceted from historical, cultural and diplomatic perspectives. Although there is trade and cultural exchange between the two countries, there has also been tension due to some issues, especially Turkey's support to Pakistan and its stance on Kashmir. Turkiye and Pakistan have strong military and diplomatic relations and Turkiye has previously supplied many weapons to Pakistan including Bayraktar TB2 drones, MİLGEM corvette warships. PNS Babur is a current example of this. If Turkiye shares or exports these bombs (GAZAP and NEB-2) with Pakistan, it can enhance Pakistan's military capability.
Business Wire
24-07-2025
- Business
- Business Wire
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX ® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland. 'The availability of CABOMETYX in the European Union for patients with previously treated advanced neuroendocrine tumors is a significant milestone as there have been limited treatment advancements in the past decade, including very few options shown to improve outcomes across a heterogenous population,' said Amy Peterson, M.D., Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer, Exelixis. 'This approval builds on the global CABOMETYX franchise and extends its benefit to even more patients in need of new treatment options. We are proud to partner with Ipsen in our shared commitment to improving the standard of care for people living with advanced, difficult-to-treat cancers.' The EC approval is based on results from the phase 3 CABINET pivotal trial, which evaluated CABOMETYX compared with placebo in two cohorts of patients with previously treated NET: advanced pNET and advanced epNET. CABINET was the basis for the U.S. Food and Drug Administration approval of CABOMETYX in March 2025 for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated epNET. About CABINET (Alliance A021602) CABINET (Randomized, Double-Blinded, Phase III Study of CAB ozantinib versus Placebo I n Patients with Advanced NE uroendocrine T umors After Progression on Prior Therapy) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and is being led and conducted by the NCI-funded Alliance for Clinical Trials in Oncology with participation from the NCI-funded National Clinical Trials Network, as part of Exelixis' collaboration through a Cooperative Research and Development Agreement with the NCI's Cancer Therapy Evaluation Program. CABINET is a multicenter, randomized, double-blinded, placebo-controlled phase 3 pivotal trial that enrolled a total of 298 patients in two separate cohorts (pNET and epNET) in the U.S. at the time of the final analysis. Patients were randomized 2:1 to cabozantinib (60 mg) or placebo; each cohort was randomized separately and had its own statistical analysis plan. The trial was stopped early after an interim analysis showed superior efficacy associated with cabozantinib as compared to placebo in each of the two cohorts. Patients with epNET had primary tumors arising in the gastrointestinal (GI) tract, lung, unknown primary sites and other organs. Patients must have had measurable disease per RECIST 1.1 criteria and must have experienced disease progression or intolerance after at least one U.S. FDA-approved line of prior systemic therapy other than somatostatin analogs. The primary endpoint in each cohort was PFS per RECIST 1.1 by blinded independent central review. Secondary endpoints included overall survival, objective response rate and safety. More information about this trial is available at About NET NET are cancers that begin in the specialized cells of the body's neuroendocrine system. 1 These cells have traits of both hormone-producing endocrine cells and nerve cells. 1 It is estimated that 161,000 to 192,000 people in the U.S. are living with unresectable, locally advanced or metastatic NET. 2 The number of people diagnosed with NET has been increasing in recent decades. 3 Functional NET release peptide hormones that can cause debilitating symptoms, like diarrhea, hypertension and flushing, while symptoms of non-functional NET are related primarily to tumor growth. 4,5,6,7,8 Most NET take years to develop and grow slowly, but eventually all patients with advanced or metastatic NET will develop refractory and progressing disease. 9,10 NET can start in the pancreas (pNET), where they tend to be more aggressive, with a five-year survival rate of only 23% for advanced disease. 1,11 NET can also develop in any part of the body, but most commonly start in the GI tract or in the lungs, where they have historically been referred to as carcinoid tumors and are more recently called epNET. 1 The five-year survival rates for advanced GI and lung NET tumors are 68% and 55%, respectively. 12,13 For advanced NET patients, treatment options include somatostatin analogs, chemotherapy, molecular targeted therapy and peptide-receptor radionuclide therapy. 14 About CABOMETYX ® (cabozantinib) In the U.S., CABOMETYX tablets are approved as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and in combination with nivolumab as a first-line treatment for patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible; for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET; and adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated epNET. CABOMETYX tablets have also received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hemorrhage: CABOMETYX can cause severe and fatal hemorrhages. The incidence of Grade 3-5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, each occurred in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or GI perforation. Thrombotic Events: CABOMETYX can cause arterial or venous thromboembolic event. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events. Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. In CABINET (n=195), hypertension occurred in 65% (26% Grade 3) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis. Diarrhea: CABOMETYX can cause diarrhea and it occurred in 62% (10% Grade 3) of treated patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1; resume at a reduced dose. Palmar-Plantar Erythrodysesthesia (PPE): CABOMETYX can cause PPE and it occurred in 45% of treated patients (13% Grade 3). Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE. Hepatotoxicity: CABOMETYX in combination with nivolumab in RCC can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. Monitor liver enzymes before initiation of treatment and periodically. Consider more frequent monitoring as compared to when the drugs are administered as single agents. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity. Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity. Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome. Osteonecrosis of the Jaw (ONJ): CABOMETYX can cause ONJ and it occurred in <1% of treated patients. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution; resume at a reduced dose. Impaired Wound Healing: CABOMETYX can cause impaired wound healing. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): CABOMETYX can cause RPLS. Perform evaluation for RPLS and diagnose by characteristic finding on MRI any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS. Thyroid Dysfunction: CABOMETYX can cause thyroid dysfunction, primarily hypothyroidism, and it occurred in 19% of treated patients (0.4% Grade 3). Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment. Hypocalcemia: CABOMETYX can cause hypocalcemia, with the highest incidence in DTC patients. Based on the safety population, hypocalcemia occurred in 13% of CABOMETYX patients (2% Grade 3 and 1% Grade 4). Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume CABOMETYX at a reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity. Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose. ADVERSE REACTIONS The most common (≥20%) adverse reactions are: CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation. CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. DRUG INTERACTIONS Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice. Strong or Moderate CYP3A4 Inducers: If coadministration with strong or moderate CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John's wort. USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose. Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment. Pediatric Use: Physeal widening has been observed in children with open growth plates when treated with CABOMETYX. Physeal and longitudinal growth monitoring is recommended in children (12 years and older) with open growth plates. Consider interrupting or discontinuing CABOMETYX if abnormalities occur. The safety and effectiveness of CABOMETYX in pediatric patients less than 12 years of age have not been established. Please see accompanying full Prescribing Information You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of CABOMETYX for patients with previously treated advanced neuroendocrine tumors; Exelixis' or its partner Ipsen's ability or plans to support these new indications for patients in Europe; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: complexities and the unpredictability of the regulatory review and approval processes in the EU and elsewhere; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib; Exelixis' dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications and their adherence to their obligations under relevant collaboration agreements; Exelixis' ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; changes in economic and business conditions; and other factors affecting Exelixis and its partners to obtain regulatory approval for cabozantinib in new indications; and other factors detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. 1 Neuroendocrine Tumors. Cleveland Clinic website. Available at: Accessed July 2025. 2 Population Estimate: Unresectable, Locally Advanced or Metastatic Extra-Pancreatic NET. June 2024 (internal data on file). 3 Pathak, S., Starr, J.S., Halfdanarson T., et al. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. September 2023;18(5):377-385. 4 Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ ®)–Patient Version. NCI website. Available at: Accessed July 2025. 5 What Is a Pancreatic Neuroendocrine Tumor? ACS website. Available at: Accessed July 2025. 6 Carcinoid Syndrome. Cleveland Clinic website. Available at: Accessed July 2025. 7 Signs and Symptoms of Gastrointestinal Carcinoid Tumors. ACS website. Available at: Accessed July 2025. 8 Signs and Symptoms of Lung Carcinoid Tumors. ACS website. Available at: Accessed July 2025. 9 McClellan, K., Chen. E.Y., Kardosh A., et al. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers. 2022;14(19):4769. 10 What is a Gastrointestinal Carcinoid Tumor? ACS website. Available at: Accessed July 2025. 11 Survival Rates for Pancreatic Neuroendocrine Tumor. ACS website. Available at: Accessed July 2025. 12 Survival Rates for Gastrointestinal Carcinoid Tumors. ACS website. Available at: Accessed July 2025. 13 Survival Rates for Lung Carcinoid Tumors. ACS website. Available at: Accessed July 2025. 14 Neuroendocrine Tumor (NET). NCI website. Available at: Accessed July 2025.
The Hindu
25-05-2025
- Politics
- The Hindu
Operation Sindoor showed India's full dominance; need to go full throttle on indigenous systems: Dr. Satheesh Reddy
India has shown complete dominance during Operation Sindoor, showcasing its air power and air defence capability, said Dr. G. Satheesh Reddy, former Secretary, Research and Development, and Chairman, Defence Research and Development Organisation (DRDO), while expressing happiness that the majority of them are indigenous systems. He cautioned that technology is changing very fast and the process of development shouldn't be so long that the technology gets outdated by the time it is inducted. Q: What is your overall assessment of Operation Sindoor? A: Firstly, it is important to understand that what has happened in this conflict is different compared to the earlier conflicts, unlike any other typical war that India has fought till date. Firstly, this was largely an airborne or aerial warfare which completely tested the air power and air defence of our country, across both manned and unmanned platforms. Secondly, for India, it has been a moment of reckoning, which has validated our domestic defence manufacturing ecosystem. We have been discussing (and executing) over the last 10 years or so the procurement and induction of more indigenous weapons. Today, this has happened to a large extent, and as the reports and press briefs and MoD releases have stated, Operation Sindoor has been fought with the majority of indigenous weapons and equipment. Our resolve over the last decade or so has been to strengthen our indigenous ecosystem, and the events in the last few years, especially the Russia-Ukraine crisis and the COVID pandemic, have again highlighted the risks in sourcing from the global supply chain. According to me, Operation Sindoor not only vindicated our Atmanirbharata resolve but also lays down a path for future procurement strategies as well. A: Overall, Operation Sindoor highlighted India's complete dominance, where in the first attack, complete terrorist camps were eliminated and in the second, the enemy air defence radars and other systems were neutralised, which was then followed by attacking their air bases and leveraging our air defence systems to prevent counter attacks on our bases. It is heartening to see that almost all attempts by the enemy to attack were neutralised by our air defence systems in mid-air itself – few that sneaked through were not as effective as they did not do any significant damage per se. Operation Sindoor proved the effectiveness of India's air defence systems (largely home-grown) while also showcasing the depth of the attack arsenal to be able to target and neutralise any base locations of the enemy. I am extremely happy that the majority of the systems used were indigenous systems. It is time for the Government and industry to go full throttle on further strengthening the indigenous defence manufacturing and R&D ecosystem. Q: We are talking a lot of Indian systems integrated with imported systems, all of which functioned seamlessly. So what stands out to you in terms of the success story? And are there any limitations or aspects that need to be focussed on? A: Firstly, Operation Sindoor witnessed multiple indigenous systems being used including air defence radars which have performed very well. The integrated operation of the complete radar network with the other elements of the air defence have worked very well, and the layered air defence with multiple weapons has also proved very effective – be it Akash, Mediurm Range Surface Air Missiles (MRSAM) or others. A: I think the command and control centre was fully aware of the situation, and to be able to track and target every incoming object with the appropriate weapon, required strong and comprehensive connectivity with the entire ecosystem. We hear the anti-drone systems have also been fully functional and were able to handle almost all the incoming drones and drone swarms. This reiterates the fact that there needs to be investment in much more advanced systems, with strong connectivity and integration, such that one system can speak to another. We need to have/create that vision and invest in niche and futuristic areas so that we can be ahead of the technology curve. The enemy understands our capability now, and this makes it all the more imperative that we continue to evolve and be more advanced in our attack and defence for the future. Q: What should be our priority in the next 5-10 years? A: Investing in niche technologies is key and intuitively investing in countering of these niche technologies as well. If there is a technology, more likely that the enemy also knows about it and hence it is important to have a counter to that as well as a deterrent or defence mechanism. A: For instance, technology developments in the unmanned systems domain (across land, sea and air) are growing at an exponential rate. We as a country need to focus on both manned, unmanned and anti-unmanned technologies in a big way - from micro drones to mini-Unmanned Aerial Vehicles (UAV) to drone swarms, to the stealthy High Altitude Long Endurance (HALE) and fighter aircraft versions and to the Unmanned Ground Vehicles (UGV) and Unmanned Underwater vehicles (UUV). We need to work vigorously towards high technology areas including hypersonics, quantum technologies, laser weapons, electromagnetics, higher precision and long-range sensors as well as highly miniaturised electronics. We need to look at technologies which can target longer ranges with cost-effective means, and we also need to look at cost-effective technologies that can counter enemy attacks by detecting and engaging them at farther ranges using both hard kill and soft kill mechanisms. We also need to consider the possibility that the future warfare may revolve around space and/or cyber only, and hence we need to parallelly continue our R&D and innovation in these areas as well, at a faster pace and with a stronger resolve. Q: If you have to pick one major system as a success story, what would that be? A: I feel more proud of the Akash missile systems as it is one of the missiles that has been developed under the Integrated Guided Missile Development programme (IGMDP). It was a project which was conceived by none other than Dr A. P. J. Abdul Kalam. I heard that our armed forces are extremely happy with the performance of that system. That for sure it is a proud moment for me and for every Indian I must say. There are other weapons also, like the other SAMs and also the BrahMos which have reportedly performed very well. Our radars and multiple sensors (both airborne and on ground) have effectively negated enemy attacks. A: I would like to add that for the plethora of weapons which are currently being developed, if they come up quickly, our armed forces will be significantly strengthened. With current indigenous content in the armed forces at 60-65%, which soon will go to 75-80%, it will be another major leap towards indigenisation. We need to work out mechanisms and processes to ensure that the procurement cycle from development to induction happens in the most efficient and effective manner. Q: So how do you ensure the development and procurements happens fast? A: Processes have to be simplified and sequential induction processes should also be removed. An integrated system should be brought in such that it is an integrated process from development to induction, and roadmap for usage of every project deliverable should be very clearly defined. This will enable the industry to plan their capacities and capabilities and come up with the production facilities right in the beginning itself. There are couple of systems where development, production and induction have happened quickly, and that should be replicated for other procurement as well. Technology is changing fast and the internal process from development to induction should not allow the technology to get outdated by the time it is inducted. A: I want to say that this war brought many positive things to India. First, many indigenous systems have been used very effectively, so the confidence of the armed forces in the indigenous equipment has reached all-time highs. I believe this will lead to more vigorous and efficient induction of indigenous systems. The morale of the scientific community today is very high, and this paves the way for the development of many more advanced systems. Industry is now more confident of getting production orders for indigenous systems, and they should hence gear up and be ready to absorb bulk orders. The international community has seen what India's capability is, so I feel the exports will also see another period of marked growth. These are significant takeaways for India from this conflict, and they have given an opportunity for growth and challenges to all stakeholders who are also gearing up to meet the same.
Yahoo
22-04-2025
- Business
- Yahoo
SMSbiotech Establishes a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense
SAN MARCOS, Calif., April 22, 2025--(BUSINESS WIRE)--SMSbiotech, Inc. is pleased to announce the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD). This is the first CRADA agreement for SMSbiotech, and it represents a significant milestone in the company's efforts to address critical military and civilian medical challenges that have existed for over a century. Under this agreement, SMSbiotech and USAMRICD will conduct joint research focused on evaluating the efficacy of SMS cells in mitigating sulfur mustard-induced pulmonary morbidities. Sulfur mustard, a chemical warfare agent, causes severe and long-lasting respiratory damage, underscoring the urgent need for effective countermeasures. "This CRADA represents a pivotal opportunity to leverage our Small Mobile Stem cell technology in addressing severe pulmonary complications caused by chemical exposure," said Dr. Abdulkader Rahmo, President of SMSbiotech. "We are honored to collaborate with USAMRICD to advance therapies that hold transformative potential for both public health and national security." SMSbiotech will provide updates on the advancement of this collaboration as they become available. About SMSbiotech SMSbiotech is a clinical-stage biotechnology company focused on developing innovative stem cell therapies for various diseases. The company's proprietary SMSc technology platform enables the delivery of stem cells to specific tissues and organs, where they can repair damaged cells and tissues. For more information about SMSbiotech, please visit View source version on Contacts Abdulkader RahmoPresident and 657-203-3030 Sign in to access your portfolio
Business Wire
22-04-2025
- Business
- Business Wire
SMSbiotech Establishes a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense
SAN MARCOS, Calif.--(BUSINESS WIRE)-- SMSbiotech, Inc. is pleased to announce the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD). This is the first CRADA agreement for SMSbiotech, and it represents a significant milestone in the company's efforts to address critical military and civilian medical challenges that have existed for over a century. 'We are honored to collaborate with USAMRICD to advance therapies that hold transformative potential for both public health and national security.' Share Under this agreement, SMSbiotech and USAMRICD will conduct joint research focused on evaluating the efficacy of SMS cells in mitigating sulfur mustard-induced pulmonary morbidities. Sulfur mustard, a chemical warfare agent, causes severe and long-lasting respiratory damage, underscoring the urgent need for effective countermeasures. 'This CRADA represents a pivotal opportunity to leverage our Small Mobile Stem cell technology in addressing severe pulmonary complications caused by chemical exposure,' said Dr. Abdulkader Rahmo, President of SMSbiotech. 'We are honored to collaborate with USAMRICD to advance therapies that hold transformative potential for both public health and national security.' SMSbiotech will provide updates on the advancement of this collaboration as they become available. About SMSbiotech SMSbiotech is a clinical-stage biotechnology company focused on developing innovative stem cell therapies for various diseases. The company's proprietary SMSc technology platform enables the delivery of stem cells to specific tissues and organs, where they can repair damaged cells and tissues. For more information about SMSbiotech, please visit
